Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Pipeline Review, H1 2018
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Pipeline Review, H1 2018
SUMMARY
According to the recently published report 'Bcl 2 Like Protein 1 - Pipeline Review, H1 2018'; Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Bcl-2-like protein 1 is a protein encoded by the BCL2L1 gene. It belongs to BCL-2 family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulate cell death by blocking the voltage-dependent anion channel by binding to it and preventing the release of the caspase activator (CYC1) from the mitochondrial membrane. It acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.
The report 'Bcl 2 Like Protein 1 - Pipeline Review, H1 2018' outlays comprehensive information on the Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Small-Cell Lung Cancer, Solid Tumor, Chronic Lymphocytic Leukemia (CLL), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Leukemias, Metastatic Melanoma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Myelofibrosis, Non-Small Cell Lung Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) and Post-Polycythemia Vera Myelofibrosis (PPV-MF).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Bcl 2 Like Protein 1 - Pipeline Review, H1 2018'; Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Bcl-2-like protein 1 is a protein encoded by the BCL2L1 gene. It belongs to BCL-2 family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulate cell death by blocking the voltage-dependent anion channel by binding to it and preventing the release of the caspase activator (CYC1) from the mitochondrial membrane. It acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.
The report 'Bcl 2 Like Protein 1 - Pipeline Review, H1 2018' outlays comprehensive information on the Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Small-Cell Lung Cancer, Solid Tumor, Chronic Lymphocytic Leukemia (CLL), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Leukemias, Metastatic Melanoma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Myelofibrosis, Non-Small Cell Lung Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) and Post-Polycythemia Vera Myelofibrosis (PPV-MF).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)
- The report reviews Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Overview
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Companies Involved in Therapeutics Development
AbbVie Inc
Ascentage Pharma Group Corp Ltd
Merrimack Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Drug Profiles
ABT-737 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APG-1252 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
navitoclax dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit BCL2 and BCLX for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WEHI-539 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Dormant Products
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Discontinued Products
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Product Development Milestones
Featured News & Press Releases
Jun 26, 2017: Ascentage Announces CFDA Grants Bcl-2/Bcl-XL inhibitor APG-1252 IND Approval for Treatment of Cancers
Dec 26, 2016: Ascentage Announces FDA Grants Bcl-2/Bcl-XL inhibitor APG-1252 IND Approval for Treatment of Cancers
Oct 13, 2016: Ascentage Pharma takes a leading position in novel drug development targeting dual pathways of apoptosis and autophagy
Apr 22, 2013: Walter And Eliza Hall Institute Scientists And Their Collaborators Develop New Potential Anti-cancer Compound WEHI-539
Nov 16, 2011: New Drug Combo Targets Multiple Cancers
Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting
Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting
Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung cancers At 2009 Asco Annual Meeting
May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting
May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting
Feb 27, 2009: Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refactory Prostate Cancer
Feb 23, 2007: Ascenta Therapeutics Presents New Clinical Data On AT-101 Monotherapy for the Treatment of Hormone-Refractory Prostate Cancer
Jan 26, 2007: Abbott And Genentech Announce Global, Integrated Research, Development And Commercialization Collaboration In Oncology
Dec 10, 2006: Ascenta Therapeutics Presents New Clinical and Biological Data on AT-101 for the Treatment of Chronic Lymphocytic Leukemia
Jun 05, 2006: Clinical Data On Ascenta Therapeutics Lead Product AT-101 Presented At The 2006 American Society For Clinical Oncology Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Overview
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Companies Involved in Therapeutics Development
AbbVie Inc
Ascentage Pharma Group Corp Ltd
Merrimack Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Drug Profiles
ABT-737 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APG-1252 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
navitoclax dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit BCL2 and BCLX for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WEHI-539 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Dormant Products
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Discontinued Products
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Product Development Milestones
Featured News & Press Releases
Jun 26, 2017: Ascentage Announces CFDA Grants Bcl-2/Bcl-XL inhibitor APG-1252 IND Approval for Treatment of Cancers
Dec 26, 2016: Ascentage Announces FDA Grants Bcl-2/Bcl-XL inhibitor APG-1252 IND Approval for Treatment of Cancers
Oct 13, 2016: Ascentage Pharma takes a leading position in novel drug development targeting dual pathways of apoptosis and autophagy
Apr 22, 2013: Walter And Eliza Hall Institute Scientists And Their Collaborators Develop New Potential Anti-cancer Compound WEHI-539
Nov 16, 2011: New Drug Combo Targets Multiple Cancers
Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting
Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting
Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung cancers At 2009 Asco Annual Meeting
May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting
May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting
Feb 27, 2009: Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refactory Prostate Cancer
Feb 23, 2007: Ascenta Therapeutics Presents New Clinical Data On AT-101 Monotherapy for the Treatment of Hormone-Refractory Prostate Cancer
Jan 26, 2007: Abbott And Genentech Announce Global, Integrated Research, Development And Commercialization Collaboration In Oncology
Dec 10, 2006: Ascenta Therapeutics Presents New Clinical and Biological Data on AT-101 for the Treatment of Chronic Lymphocytic Leukemia
Jun 05, 2006: Clinical Data On Ascenta Therapeutics Lead Product AT-101 Presented At The 2006 American Society For Clinical Oncology Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AbbVie Inc, H1 2018
Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018
Pipeline by Merrimack Pharmaceuticals Inc, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AbbVie Inc, H1 2018
Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018
Pipeline by Merrimack Pharmaceuticals Inc, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
AbbVie Inc
Ascentage Pharma Group Corp Ltd
Merrimack Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
AbbVie Inc
Ascentage Pharma Group Corp Ltd
Merrimack Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
